Immuno Oncology Assays Market is estimated to increase at a Compounded Annual Growth Rate of 11.1% CAGR over the forecast period from 2024 to 2030
The Immuno Oncology Assays Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments- By Products and Services (Consumables, Instruments, Software & Services), By Technology (PCR, Immunoassay, NGS, ISH, Flow Cytometry), By Indication (Lung Cancer, Breast Cancer, Colorectal Cancer, Bladder Cancer, Melanoma, Others), By Application (Research Applications, Clinical Diagnostics).
An Introduction to Immuno Oncology Assays Market in 2024
Immuno-oncology assays play a pivotal role in cancer research and drug development, enabling the characterization of tumor-immune interactions, immune cell profiling, and assessment of immunotherapy efficacy. In 2024, advancements in immuno-oncology assay technologies have led to the development of multiplexed assays that simultaneously measure multiple immune markers, cytokines, and cellular functions in tumor samples and peripheral blood specimens. High-throughput platforms, such as flow cytometry, mass cytometry (CyTOF), and multiplex immunofluorescence, enable comprehensive immune profiling and biomarker discovery, facilitating the identification of predictive and prognostic signatures for patient stratification and treatment selection. Furthermore, organoid and patient-derived xenograft (PDX) models provide valuable preclinical platforms for evaluating immunotherapy responses and studying tumor-immune system interactions in a physiologically relevant context. As the field of immuno-oncology continues to evolve, the integration of advanced assay technologies and computational analysis tools holds promise for accelerating the development of novel immunotherapies and personalized treatment strategies for cancer patients.
Market Trend: Advancements in Biomarker Discovery and Personalized Medicine
A prominent trend in the immuno-oncology assays market is the advancements in biomarker discovery and personalized medicine. As the field of immuno-oncology continues to evolve rapidly, there is increasing recognition of the importance of identifying predictive biomarkers and understanding the tumor-immune microenvironment to guide treatment decisions and improve patient outcomes. Immuno-oncology assays play a crucial role in characterizing immune responses, profiling tumor antigens, and assessing immune checkpoint pathways, enabling researchers and clinicians to develop personalized immunotherapy strategies tailored to individual patients. The trend towards biomarker-driven and personalized approaches in immuno-oncology drives market demand for innovative assays capable of accurately measuring immune parameters and predicting treatment responses.
Market Driver: Growing Adoption of Immunotherapy and Checkpoint Inhibitors
A primary driver fueling the growth of the immuno-oncology assays market is the growing adoption of immunotherapy and immune checkpoint inhibitors in cancer treatment. Immunotherapy has emerged as a transformative approach in cancer therapy, harnessing the body's immune system to recognize and eradicate cancer cells. Immune checkpoint inhibitors, such as PD-1/PD-L1 inhibitors and CTLA-4 inhibitors, have demonstrated remarkable efficacy in a variety of cancer types, including melanoma, lung cancer, and bladder cancer. Immuno-oncology assays play a critical role in assessing the expression of immune checkpoint proteins, evaluating tumor-infiltrating immune cells, and predicting patient responses to immunotherapy agents. With the expanding use of immunotherapy in clinical practice and ongoing research efforts to develop novel immunotherapeutic agents, there is a growing demand for immuno-oncology assays that can accurately assess immune function and guide treatment selection in cancer patients.
Market Opportunity: Development of Multiplex Assay Panels for Comprehensive Immune Profiling
An enticing opportunity within the immuno-oncology assays market lies in the development of multiplex assay panels for comprehensive immune profiling. Multiplex assays enable the simultaneous measurement of multiple immune markers, cytokines, and tumor antigens from a single sample, providing comprehensive insights into the tumor-immune microenvironment and immune response dynamics. By combining multiple biomarkers in a single assay panel, researchers and clinicians can obtain a more holistic view of the immune landscape and identify predictive biomarker signatures associated with treatment outcomes and prognosis. Additionally, multiplex assay panels facilitate efficient use of limited sample volumes, reduce assay variability, and enable high-throughput analysis of patient samples, making them valuable tools for translational research and clinical decision-making in immuno-oncology. Investing in the development of multiplex immuno-oncology assay panels presents opportunities for market differentiation, collaboration with pharmaceutical companies and academic institutions, and advancement of personalized medicine approaches in cancer immunotherapy.
Immuno Oncology Assays Market Share Analysis: Immunoassay Technology is the fastest growing segment over the forecast period to 2030
The Immunoassay Technology segment is experiencing the most rapid growth within the Immuno Oncology Assays Market, and several factors contribute to this trend. Firstly, immunoassays offer high sensitivity and specificity in detecting and quantifying biomarkers associated with immune responses, making them indispensable tools in immuno-oncology research and clinical diagnostics. As the understanding of the complex interactions between the immune system and cancer continues to evolve, there is an increasing demand for immunoassays capable of measuring various immune-related parameters such as cytokines, immune checkpoint proteins, and circulating tumor cells. Moreover, immunoassay technology has witnessed significant advancements in recent years, including the development of multiplex immunoassay platforms that allow simultaneous detection of multiple analytes from small sample volumes, thereby enabling comprehensive immune profiling in cancer patients. Additionally, the rising prevalence of cancer worldwide, particularly lung cancer, breast cancer, melanoma, and colorectal cancer, has driven the demand for immunoassays for early detection, prognosis, and treatment monitoring. Furthermore, the expanding application of immunoassays in both research and clinical settings, coupled with the availability of user-friendly immunoassay kits and automated immunoassay instruments, has contributed to the widespread adoption of this technology across the immuno-oncology community. Overall, the Immunoassay Technology segment is experiencing rapid growth due to its essential role in advancing immuno-oncology research and improving cancer diagnostics and patient management.
Immuno Oncology Assays Competitive Analysis
The market research study provides in-depth insights into leading companies including the SWOT analyses, product profile, financial details, and recent developments acrossAbbott Laboratories Inc, Agilent Technologies Inc, ASURAGEN Inc, bioMérieux SA, Bio-Rad Laboratories Inc, Charles River Laboratories Inc, Creative Biolabs, F. Hoffmann-La Roche Ltd, Guardant Health Inc, HTG Molecular Diagnostics Inc, Illumina Inc, Invivoscribe Inc, Merck Millipore, Meso Scale Diagnostics Llc, Myriad Genetics Inc, NanoString Technologies Inc, NMI Technologietransfer GmbH, PerkinElmer Inc, Qiagen N.V., ReachBio LLC , Sartorius AG, Seegene Inc, Thermo Fisher Scientific Inc
Immuno Oncology Assays Market Segmentation
By Products and Services
Consumables
Instruments
Software & Services
By Technology
PCR
Immunoassay
NGS
ISH
Flow Cytometry
By Indication
Lung Cancer
Breast Cancer
Colorectal Cancer
Bladder Cancer
Melanoma
Others
By Application
Research Applications
Clinical Diagnostics
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
Immuno Oncology Assays Market Companies
Abbott Laboratories Inc
Agilent Technologies Inc
ASURAGEN Inc
bioMérieux SA
Bio-Rad Laboratories Inc
Charles River Laboratories Inc
Creative Biolabs
F. Hoffmann-La Roche Ltd
Guardant Health Inc
HTG Molecular Diagnostics Inc
Illumina Inc
Invivoscribe Inc
Merck Millipore
Meso Scale Diagnostics Llc
Myriad Genetics Inc
NanoString Technologies Inc
NMI Technologietransfer GmbH
PerkinElmer Inc
Qiagen N.V.
ReachBio LLC
Sartorius AG
Seegene Inc
Thermo Fisher Scientific Inc
Reasons to Buy the Immuno Oncology Assays Market Study
• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Immuno Oncology Assays Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Immuno Oncology Assays Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.
TABLE OF CONTENTS
1 Introduction to 2024 Immuno Oncology Assays Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Covered
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain
2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations
3 Executive Summary
3.1 Global Immuno Oncology Assays Market Size Outlook, $ Million, 2021 to 2030
3.2 Immuno Oncology Assays Market Outlook by Type, $ Million, 2021 to 2030
3.3 Immuno Oncology Assays Market Outlook by Product, $ Million, 2021 to 2030
3.4 Immuno Oncology Assays Market Outlook by Application, $ Million, 2021 to 2030
3.5 Immuno Oncology Assays Market Outlook by Key Countries, $ Million, 2021 to 2030
4 Market Dynamics
4.1 Key Driving Forces of Immuno Oncology Assays Industry
4.2 Key Market Trends in Immuno Oncology Assays Industry
4.3 Potential Opportunities in Immuno Oncology Assays Industry
4.4 Key Challenges in Immuno Oncology Assays Industry
5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Immuno Oncology Assays Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook
6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts
7 Global Immuno Oncology Assays Market Outlook by Segments
7.1 Immuno Oncology Assays Market Outlook by Segments, $ Million, 2021- 2030
By Products and Services
Consumables
Instruments
Software & Services
By Technology
PCR
Immunoassay
NGS
ISH
Flow Cytometry
By Indication
Lung Cancer
Breast Cancer
Colorectal Cancer
Bladder Cancer
Melanoma
Others
By Application
Research Applications
Clinical Diagnostics
8 North America Immuno Oncology Assays Market Analysis and Outlook To 2030
8.1 Introduction to North America Immuno Oncology Assays Markets in 2024
8.2 North America Immuno Oncology Assays Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Immuno Oncology Assays Market size Outlook by Segments, 2021-2030
By Products and Services
Consumables
Instruments
Software & Services
By Technology
PCR
Immunoassay
NGS
ISH
Flow Cytometry
By Indication
Lung Cancer
Breast Cancer
Colorectal Cancer
Bladder Cancer
Melanoma
Others
By Application
Research Applications
Clinical Diagnostics
9 Europe Immuno Oncology Assays Market Analysis and Outlook To 2030
9.1 Introduction to Europe Immuno Oncology Assays Markets in 2024
9.2 Europe Immuno Oncology Assays Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Immuno Oncology Assays Market Size Outlook by Segments, 2021-2030
By Products and Services
Consumables
Instruments
Software & Services
By Technology
PCR
Immunoassay
NGS
ISH
Flow Cytometry
By Indication
Lung Cancer
Breast Cancer
Colorectal Cancer
Bladder Cancer
Melanoma
Others
By Application
Research Applications
Clinical Diagnostics
10 Asia Pacific Immuno Oncology Assays Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Immuno Oncology Assays Markets in 2024
10.2 Asia Pacific Immuno Oncology Assays Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Immuno Oncology Assays Market size Outlook by Segments, 2021-2030
By Products and Services
Consumables
Instruments
Software & Services
By Technology
PCR
Immunoassay
NGS
ISH
Flow Cytometry
By Indication
Lung Cancer
Breast Cancer
Colorectal Cancer
Bladder Cancer
Melanoma
Others
By Application
Research Applications
Clinical Diagnostics
11 South America Immuno Oncology Assays Market Analysis and Outlook To 2030
11.1 Introduction to South America Immuno Oncology Assays Markets in 2024
11.2 South America Immuno Oncology Assays Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Immuno Oncology Assays Market size Outlook by Segments, 2021-2030
By Products and Services
Consumables
Instruments
Software & Services
By Technology
PCR
Immunoassay
NGS
ISH
Flow Cytometry
By Indication
Lung Cancer
Breast Cancer
Colorectal Cancer
Bladder Cancer
Melanoma
Others
By Application
Research Applications
Clinical Diagnostics
12 Middle East and Africa Immuno Oncology Assays Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Immuno Oncology Assays Markets in 2024
12.2 Middle East and Africa Immuno Oncology Assays Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Immuno Oncology Assays Market size Outlook by Segments, 2021-2030
By Products and Services
Consumables
Instruments
Software & Services
By Technology
PCR
Immunoassay
NGS
ISH
Flow Cytometry
By Indication
Lung Cancer
Breast Cancer
Colorectal Cancer
Bladder Cancer
Melanoma
Others
By Application
Research Applications
Clinical Diagnostics
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Abbott Laboratories Inc
Agilent Technologies Inc
ASURAGEN Inc
bioMérieux SA
Bio-Rad Laboratories Inc
Charles River Laboratories Inc
Creative Biolabs
F. Hoffmann-La Roche Ltd
Guardant Health Inc
HTG Molecular Diagnostics Inc
Illumina Inc
Invivoscribe Inc
Merck Millipore
Meso Scale Diagnostics Llc
Myriad Genetics Inc
NanoString Technologies Inc
NMI Technologietransfer GmbH
PerkinElmer Inc
Qiagen N.V.
ReachBio LLC
Sartorius AG
Seegene Inc
Thermo Fisher Scientific Inc
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise
By Products and Services
Consumables
Instruments
Software & Services
By Technology
PCR
Immunoassay
NGS
ISH
Flow Cytometry
By Indication
Lung Cancer
Breast Cancer
Colorectal Cancer
Bladder Cancer
Melanoma
Others
By Application
Research Applications
Clinical Diagnostics
Countries Analyzed
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
